BioMarin presents report on phase 2 study of Vosoritide
2016-10-20Research
BioMarin has issued a new press release with data on the phase 2 clinical trial for Vosoritide, during the ASHG 2016 meeting. Read all about it here.
State of the art in achondroplasia
2016-06-30Research
This is a summary of the current state of drug development in achondroplasia.
BMN-111 Phase 2: study 111-202 and extension study 111-205
2016-05-13Research
There are two studies by BioMarin in Phase 2 clinical trials where BMN-111 (vosoritide) is being administered. They have different objectives and durations, which can be consulted here.
Update in multicenter study from BioMarin
2016-04-21Research
Biomarin is sponsoring and coordinating a study for the study of growth patterns of Achondroplasia in children and adolescents in several centers in Europe and North America. Find out where it's being conduced here.
Vosoritide for Achondroplasia - Research and Development day 20th April 2016
2016-04-21Research
On Research and Development Day BioMarin presented updates for Vosoritide (BMN-111) clinical trials. See the summary of these updates here.
ReAch Achondroplasia Registry
2016-04-11Research
Prof. Krejcis team is researching FGF signaling mechanisms, in particular, pathological FGFRs, such as FGFR3, which causes achondroplasia. His team also manages ReACH, standing for Registry of Achondroplasia, which means to serve as a tool for clinicians and healthcare providers to conduct research.
